Skip to content
FIND A HEALTH VALLEY ACTOR

Limula wins a prestigious EIC grant of €4.7 million

By combining its novel bioreactor with state-of-the-art sensors and predictive data intelligence, Limula will add significant value to its cell & gene therapy manufacturing solution, paving the way for in-process control for the production of highly personalised cancer treatments.

Read More

CHUV strengthens its strategy to fight cancer

Solange Peters Chuv

The University Hospital of Vaud (CHUV) in Lausanne is expanding its strategy to better fight all forms of cancer. The institution is opening three new interdisciplinary oncology centers, focusing on the brain and spinal cord, liver and pancreas, and ENT and cervicofacial tumors.   The University Hospital of Vau, CHUV, had already been a pioneer…

Read More

BioAlps at OM Pharma

BioAlps OM Pharma 4à6

On 9 June 2022, during a BioAlps’ 4à6 event, the Heath Valley Community had the opportunity to visit OM Pharma in Geneva.   OM Pharma is a leader in the prevention of recurrent respiratory and urinary tract infections with products regulating the immune system based on oral bacterial extracts. Broncho-Vaxom® and Uro Vaxom® are marketed…

Read More

Cytiva opens a new production site in Grens (VD)

Cityva 3D

Cytiva opens its new 7,400 m2 production facility in Grens, Switzerland, on 31 May 2022.   The site will manufacture single-use kits for the Sepax and Sefia cell processing systems, as well as consumables for the Xuri cell expansion systems. The new site will be home to 250 employees and house the Centre of Excellence…

Read More

Votes are open for the TOP 100 Swiss Startups! 

Top Swiss Startups

What is your favorite swiss startup?   Every year the TOP 100 Swiss Startup Award showcases the 100 most innovative and promising Swiss startups. 438 Swiss deeptech startups have been featured in the ranking over the past decade. So far, they have created 11100 jobs and raised CHF 6.1 billion. In 2022, 269 Life Sciences…

Read More

Pr. Antoine Geissbuhler is the new BioAlps’ President

Prof. Antoine Geissbuhler BioAlps President

A Digital Health specialist to promote the Swiss Health Valley and the number one and most diversified Life Sciences Cluster in Europe   After a selection process of several months, BioAlps’ Executive Committee identified a strong candidate to take over the role of Mr Claude Clément as President of the BioAlps Association. On Thursday 19…

Read More

Alithea Genomics closes a CHF 1 million seed round

Alithea Genomics

Alithea Genomics, a Lausanne-based fast-growing, emerging leader in the field of RNA sequencing and transcriptomics analysis, announced the closing of a CHF 1 million seed financing round led by the Novalis Biotech Acceleration fund, with the participation of Swiss-based private investors.   Alithea has developed a proprietary technology called Bulk RNA Barcoding and sequencing (BRB-seq), which enables the preparation…

Read More

Dr. Andrea Pfeifer received the Aenne Burda Award

Dr. Andrea Pfeifer Ac Immune SA

The CEO and Director of AC Immune SA was recognized for her work to find treatments for Alzheimer’s disease   AC Immune SA (NASDAQ: ACIU), a Lausanne-based clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced that Dr. Andrea Pfeifer, CEO and a Director of AC Immune, was awarded the prestigious Aenne Burda Award…

Read More

Kodiak Sciences and Lonza open a new facility in Visp

Kodiak Sciences and Lonza open a new facility in Visp

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat retinal diseases, and Lonza announced on 17 May 2022 the opening of a new, custom-built, bioconjugation facility within Lonza’s Ibex® Dedicate manufacturing complex in Visp, Switzerland.   The facility will play a key role in the scaled…

Read More

Swiss biotech companies attracted investments of $3.33 billion in 2021

Biotech

Last year was ‘the second best year in terms of fundraising’, according to the Swiss Biotech Association. The sector benefited from a “still strong” international contribution.   Of the $3.33 billion, $2.51 billion was invested in listed companies, including Sophia Genetics in Lausanne, with $234 million following its initial public offering (IPO) and its follow-up,…

Read More